Drug Database
ST

stepronin (Tiase / Tioten)

✓ Approved

Mediolanum Farmaceutici Spa · Small Molecule · Small Molecule

What is stepronin?

stepronin is a small molecule developed by Mediolanum Farmaceutici Spa. It is approved for therapeutic indications.

Drug Profile

Brand NamesTiase, Tioten
CompanyMediolanum Farmaceutici Spa
Drug ClassSmall Molecule
StatusApproved

Therapeutic Indications

stepronin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Hepatobiliary disordersHepatic function abnormal✓ Approved

Related Research Articles

PubMedTransplantation proceedings2000-01-05

Anti-human immunodeficiency virus activity of a new immunosuppressant drug called stepronin.

de Giorgi L L, Habeshaw J A JA, Broadhurst K K, Carminati P P et al.

PubMedAllergy1996-04-01

Accelerated cell-mediated broncho-obstructive reaction to inhaled stepronin: a case report.

Romano A A, Di Fonso M M, Mormile F F, Quaratino D D et al.

We describe the case of a 20-year-old man who developed an obstructive bronchial reaction accompanied by a maculopapular facial rash 8 h after an aerosol treatment with the mucolytic drug stepronin. The results of intradermal and patch testing with stepronin, together with those of bronchial challenge and histologic findings in patch-tested skin, indicate that the patient's reaction involved an accelerated cell-mediated mechanism of hypersensitivity. Bronchial challenges with methacholine demonstrated a transient increase in nonspecific bronchial hyperreactivity.

PubMedTransplantation proceedings1994-12-01

Immunosuppressive effect of stepronin (TS-5010680) in mice.

de Giorgi L L, Arrigoni-Martelli E E, Matossian-Rogers A A

PubMedRespiration; international review of thoracic diseases1994-01-01

An expectorant, stepronin, reduces airway secretion in vitro.

Yamada K K, Satoh M M, Shimura S S, Sasaki T T et al.

Stepronin (SPN) is clinically used as an expectorant, and thenoic acid (TA) is its metabolite. We examined the effects of these drugs on the bioelectric parameters [potential difference (PD), short circuit current (SCC), conductance (G)] of the posterior epithelial membrane of canine trachea and on those of the mucus glycoprotein secretion from feline tracheal isolated glands. PD and SCC were obtained using an Ussing chamber and G was calculated as the ratio SCC/PD. Neither SPN nor TA significantly altered the baseline values of PD and SCC. However, in the mucosal solution, both SPN and TA significantly inhibited PD and SCC evoked by isoproterenol (ISOP), whereas G remained unchanged. Amirolide did not alter the inhibitory action of SPN and TA. Mucus glycoprotein secretion from isolated glands was estimated by measuring trichloride acetic acid-precipitable [3H]-glycoconjugates. SPN and TA significantly reduced mucus glycoprotein secretion. Further, when stimulated by methacholine, these agents significantly inhibited mucus glycoprotein secretion from isolated glands. These findings suggest that SPN inhibits airway secretion in vitro by both decreasing Cl- secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands.

PubMedContact dermatitis1993-09-01

Delayed hypersensitivity to stepronin: a case report.

Romano A A, Pietrantonio F F, di Fonso M M, Pocobelli D D et al.

PubMedLa Clinica terapeutica1990-11-15

[A controlled clinical study on the efficacy and tolerability of stepronin in chronic alcoholic liver diseases].

De Rensis L L, Schianchi L L, Assunto A A, Antenora G G et al.

A group of 15 hospitalized chronic alcoholics was treated for 30 days with twice daily doses of 840 mg stepronin and was compared to 15 patients receiving placebo. The favorable results of this treatment are reported together with statistically significant changes of laboratory tests.

+6 more articles available with a free account

Sign up free to view all articles →

Ask about stepronin